32 results about "Spasticity" patented technology

A high concentration baclofen solution is provided suitable for therapeutic use in a medical setting. A high concentration solution of baclofen in multivalent physiological ion solution such as artificial cerebrospinal fluid is provided with concentrations of baclofen of 10 mg/ml. Artificial cerebrospinal fluid is particularly advantageous as a baclofen solvent. A medical package is also provided for baclofen delivery to patients suffering from spasticity.

This invention provides methods for inhibiting or reducing thalamic damage in a subject comprising administering to the subject an amount of laquinimod, wherein the subject is a human patient afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome who has been determined to have thalamic damage at baseline, a subject afflicted with a disease or disorder other than a form of multiple sclerosis or a clinically isolated syndrome, or a subject not afflicted with a form of multiple sclerosis or a presenting clinically isolated syndrome, and laquinimod and laquinimod pharmaceutical compositions for use thereof. This invention also provides methods for inhibiting or reducing tremor or spasticity in a subject afflicted by tremor or spasticity, comprising administering to the subject an amount of laquinimod, and laquinimod and laquinimod pharmaceutical compositions for use thereof.

A spasticity measurement apparatus includes: a leg mounting fixture including a lower leg mounting portion mounted on a lower leg of a subject for fixation, and a foot receiving portion coupled to a lower end portion of the lower leg mounting portion and having a heel receiving portion and a toe receiving portion for respectively receiving a heel and a toe of a foot leading to the lower leg, the toe receiving portion being disposed relatively rotatably around the heel receiving portion in an approaching rotation direction bringing the toe receiving portion closer to the lower leg mounting portion; a rotation inhibition apparatus inhibiting relative rotation when the foot receiving portion rotates relative to the lower leg mounting portion in the approaching direction; and a muscular contraction force measurement apparatus measuring a muscular contraction force acting in a rotation direction.

The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R¹ and R² are each independently H or alkyl; Y is an alkyl group. CONR³R⁴, COOR⁵SO₂NR¹⁶R¹⁷, NHSO₂R¹⁸ or CN; X is an aryl or heteroaryl group, each of which may be optionally substituted with one or more substituents selected from (CH2)_mZ where Z is halogen, OH, CN, alkyl, alkoxy, NO₂, CF₃, CONR⁶R⁷, CN, NR⁸R⁹, COOR¹⁰ or NHCOR¹¹ and m is 0 to 3; R³ to R¹¹ are each independently H, alkyl or aryl, wherein said alkyl and aryl groups are optionally substituted by one or more substituents selected from halogen, OH, CN, alkyl, alkoxy, NO₂, CF₃, CONR¹²R¹³, CN, NH₂, COOR¹⁴, NHCOR¹⁵, and CN; R¹² to R¹⁸ are each independently H or alkyl, more preferably H or Me; n is 1 to 6; wherein the compound is other than 3′,5′-dimethyl-4-(1,1-dimethylheptyl)-1,1′-biphenyl-2-ol. Further aspects of the invention related to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

The invention provides novel medical application of butylphthalide, i.e. the application of the butylphthalide in the preparation of a medicament for treating the bronchial asthma. The experimental research on the spasmolysis of the butylphthalide on the isolated tracheal smooth muscle of a guinea pig and the influence of the butylphthalide on the incubation period of asthma of the guinea pig shows that the butylphthalide in the concentration range of 3.68*10-6 to 3.68*10-4g/mL has obvious spasmolysis on the tracheal smooth muscle of the guinea pig in the isolated spasticity caused by 5*10-6g/mL of acetylcholine or histamine. On the basis of continuously applying the butylphthalide to the guinea pig which is sensitive for the acetylcholine and the histamine for 10 days, a mixture of the acetylcholine and the histamine is atomized and sucked and the incubation period of asthma is observed. A result shows that 30 mg/kg and 90 mg/kg of butylphthalide has an effect of relieving the tracheospasm of the guinea pig, which is caused by the acetylcholine and the histamine. Therefore, the butylphthalide has a treatment effect on the asthma guinea pig and the treatment effect of the butylphthalide on the asthma guinea pig is related to the effect of inhibiting Ca2+ inner flow and expanded tracheal smooth muscle of the butylphthalide.

The present invention discloses a motion delay and tremor quantitatively detecting device and detecting method, and relates to the field of medical instruments. The motion delay and tremor quantitatively detecting method and device disclosed by the present invention are implemented through cooperation of software in combination with hardware electronic devices. According to the scheme of the present invention, fine pen data input by a subject by using an electronic pen is captured and analyzed through deep learning and big data methods, and the motion time, the median motion speed, the acceleration maximum value, the tremor frequency, the tremor amplitude, and the position (x,y) of the pen during handwriting of the subject, a motion trajectory within 1 cm from the plane written by using the electronic writing input device, dynamics indicators such as the speed and the acceleration, and other data are obtained, so that a solution of an auxiliary detection and medication effect trackingmethod for quantifiable objective indicators of the motion delay and tremor (especially in the early stages) is provided from the perspective of typical motion delay and tremor core symptoms such as the tremor, the motion delay, the spasticity and the like.

The invention relates to the technical field of medical health-care equipment, and particularly relates to a skin scraping plate used for alleviating rheumatic pain, arthralgia, and numbness spasm, and a manufacturing method thereof. The skin scraping plate is made of liquidambar formosana and is obtained through the immersion of eucommia, buck grass, Gaultheria yunnanensis, and liquor. The skin scraping plate is made of liquidambar formosana, the liquidambar formosana itself has the effects of dispelling wind and eliminating dampness, and dredging collaterals and activating blood circulation, and the skin scraping plate is soaked by the eucommia, buck grass, and Gaultheria yunnanensis, the above three plants have the treatment effects on wind-cold-dampness arthralgia, tendon and vessel spasm pain, and traumatic injury, so that the skin scraping plate has good treatment effects on rheumatic pain, arthralgia, and numbness spasm. The skin scraping plate is simple in use and can directly scrap the ache or discomfort part, and compared with a skin scraping device made of horns and jade, the skin scraping plate provided has the characteristic of excellent treatment effects. In addition, the skin scraping plate is made of wood, so that the skin scraping plate is low in cost and can meet the use demands of a lot of consumers.

The present invention relates to a portable devise that is able to quantify spasticity. In one aspect, the invention allows clinicians to objectively quantify spasticity in an accurate and repeatable manner. The device is designed to accommodate for different limb sizes and includes an accelerometer and a force sensing resistor to obtain quantitative data. The device further includes a data acquisition module where the data collected can be processed and sent to an output device.

The apparatus provides a proper step width for patients during gait training with neurological disorders, such as spasticity or paraparesis of the lower extremities. The apparatus provides proprioceptive feedback through the ankles during gait training with an assistive device (cane, walker, or parallel bars). The apparatus can be adjusted to different step widths depending on the patient and the physical therapist's recommendation. The result would be an improvement in the patient's gait pattern over time (with less risk of injury to the patient) and an improvement in the method used by the physical therapist for gait training for this problem.

The invention discloses a conditioning medicine aiming at pain and rheumatism and a preparation method of the conditioning medicine. The conditioning medicine consists of the following components in percentage by weight: 20-40 percent of coriolus versicolor mycelium polysaccharide, 15-30 percent of needle mushroom mycelium polysaccharide, 20-35 percent of polygahatous polysaccharide and 15-35 percent of rheum officinale polysaccharide. The preparation method comprises the following steps: respectively extracting the coriolus versicolor mycelium polysaccharide, needle mushroom mycelium polysaccharide, polygahatous polysaccharide and rheum officinale polysaccharide, and preparing according to the ratio. The conditioning medicine disclosed by the invention is low in cost and does not have any toxic or side effect, can achieve the effects of improving the human immunologic function, relieving swelling and pain, diminishing inflammation, expelling wind and eliminating dampness and diminishing inflammation and relieving pain and has obvious effects on traumatic injury, lumbar muscle degeneration, sciatica, prosopalgia, facial palsy and spasticity, rheumatoid arthritis, antitumor immunological therapy, internal and external hemorrhoids and colitis. The conditioning medicine is taken by adults 2-3 times per day, 1-2 grains of the medicine are taken each time, and the medicine can be taken for a long time.

The invention relates to the technical field of medical rehabilitation equipment, in particular to a flexor spasticity drafting device after apoplectic hemiplegia. The device includes: a forearm assembly, wherein the forearm assembly comprises a forearm connecting pipe, a first ball joint and a forearm protector, and the forearm connecting pipe is connected to the forearm protector through the first ball joint; a big arm assembly, wherein the big arm assembly comprises a big arm connecting pipe, a second ball joint and a big arm protector, and the big arm connecting pipe is connected to the big arm protector through the second ball joint. The forearm connecting pipe is hinged to the big arm connecting pipe through a rotating shaft; elastic pieces are respectively arranged in the forearm connecting pipe and the big arm connecting pipe; and the forearm connecting pipe and the big arm connecting pipe are jointly hinged to a control assembly for drafting the big arm and the forearm. The drafting device is high in flexibility and good in body protection, the technical purpose of flexor traction is achieved, and secondary damage of a mechanical rigid structure to a patient is overcome.

The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof : (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substituted by one or more OH groups; X is a group selected from —C≡C—(CH₂)_p—; —C(R⁵)═C(R⁶)—(CH₂)_q—; and —C(R⁵)(R⁶)C(R⁷)(R⁸)—(CH²)r—; where each of R⁵, R⁶, R⁷ and is independently II or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR²; CONR³R⁴; SO₂NR⁹R¹⁰; NR¹²COR¹³; NR¹⁴SO₂R¹⁵; and a heterocyclic group selected from oxadiazolyl, thiazolyl, isothiazolyl, oxazolyl, iso-oxazolyl, pyrazolyl and imidazolyl; where each of R², R³ and R⁴ is independently H or alkyl; or R³ and R⁴ are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group optionally containing one or more further groups selected from O, N, CO and S, and where each of R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄ and R₁₅ is independently H or alkyl. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, pain, or for controlling spasticity or tremors, for example, spasticity in MS.

Provided is air pressurization equipment that is easily installed on the body, has excellent stability during use, and is for spasticity prevention. Equipment that is to be installed on a wrist or a limb that includes a wrist is an airtight airbag that is configured from a cylindrical bag body 11 that expands or contracts as a result of supply or expulsion of air. The bag body 11 is formed from asynthetic resin sheet. A pressurization part that communicates with open parts 16 that are on either side is formed at an inside center hole in the bag body 11. When the equipment is installed, a limbis inserted from an open part 16 of the expanded cylindrical bag body 11, the inside center hole in the cylindrical bag body 11 is made to contact the body, and the equipment is moved in the insertion or removal direction while being rotated, is held in a desired position, and, in that state, pressurizes and constrains an affected area.

The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of spasticity.